Skip to main content

Advertisement

SpringerLink
Log in

Outpacing Cancer

  • News
  • Published:

From Nature Medicine

View current issue Submit your manuscript

In the late 1990s the drug gefitinib became a new tool in treating the most common type of lung cancer, called non–small cell lung cancer. But doctors found that even with continued gefitinib treatment, some patients experienced a cancer relapse within a year. For the past several years, researchers have been working to uncover why these patients lost sensitivity to gefitinib and seeking how to overcome resistance to the drug. Kirsten Dorans reports on the strategies scientists are developing to outpace continually evolving cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Druker, B.J. et al. Blood 94 (Suppl.), 368a (1999).

    Google Scholar 

  2. Sawyers, C.L. N. Engl. J. Med. 340, 1330–1340 (1999).

    Article  CAS  Google Scholar 

  3. Shah, N.P. et al. Cancer Cell 2, 117–125 (2002).

    Article  CAS  Google Scholar 

  4. Talpaz, M. et al. N. Engl. J. Med. 354, 2531–2541 (2006).

    Article  CAS  Google Scholar 

  5. Kantarjian, H. et al. N. Engl. J. Med. 354, 2542–2551 (2006).

    Article  Google Scholar 

  6. Arteaga, C.L. Exp. Cell Res. 284, 122–130 (2003).

    Article  CAS  Google Scholar 

  7. Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).

    Article  CAS  Google Scholar 

  8. Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).

    Article  CAS  Google Scholar 

  9. Paez, J.G. et al. Science 304, 1497–1500 (2004).

    Article  CAS  Google Scholar 

  10. Pao, W. et al. PLoS Med. 2, e17 (2005).

    Article  Google Scholar 

  11. Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).

    Article  CAS  Google Scholar 

  12. Pao, W. et al. Proc. Natl. Acad. Sci. USA 2, e73 (2005).

    Google Scholar 

  13. Costa, D.B. et al. PLoS Med. 4, 1669–1679 (2007).

    Article  CAS  Google Scholar 

  14. Balak, M.N. et al. Clin. Cancer Res. 12, 6494–6501 (2006).

    Article  CAS  Google Scholar 

  15. Bean, J. et al. Clin. Cancer Res. 14, 7519–7525 (2008).

    Article  CAS  Google Scholar 

  16. Bell, D.W. et al. Nat. Genet. 12, 1315–1316 (2005).

    Article  Google Scholar 

  17. Yun, C.H. et al. Proc. Natl. Acad. Sci. USA 105, 2070–2075 (2008).

    Article  CAS  Google Scholar 

  18. Engelman, J.A. et al. Science 316, 1039–1043 (2007).

    Article  CAS  Google Scholar 

  19. Bean, J. et al. Proc. Natl. Acad. Sci. USA 104, 20932–20937 (2007).

    Article  CAS  Google Scholar 

  20. Carter, T.A. et al. Proc. Natl. Acad. Sci. USA 102, 11011–11016 (2005).

    Article  CAS  Google Scholar 

  21. Maheswaran, S. et al. N. Engl. J. Med. 359, 366–377 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kirsten Dorans is an assistant editor at Lab Animal, a Nature Publishing Group publication, based in New York.,

    Kirsten Dorans

Authors
  1. Kirsten Dorans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dorans, K. Outpacing Cancer. Nat Med 15, 718–722 (2009). https://doi.org/10.1038/nm0709-718

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0709-718

  • Springer Nature America, Inc.

Search

Navigation